Triple negative breast cancer has a worse prognosis and often relapses early compared with other subtypes of breast cancer. It is characterized by the lack of expression of estrogen receptor, progesterone receptor, and HER2. Several agents are currently being investigated as potential therapeutic agents for the treatment of TNBC. A promising treatment strategy in breast cancer is the use of immunotherapy. See here Alice, she had a very agressive relapse of TNBC before she came to our clinic. She received a combined immunotherapeutic treatment approach and is now almost in complete remission! We are so happy for you!

Nous sommes venus à la clinique d’oncologie Hallwang car Alice était traitée en France pour une récidive très agressive d’un cancer du sein triple négatif en Avril 2016. Malheureusement le traitement de chimiothérapie entrepris en France n’a donné aucun résultat et il était impossible d’entreprendre une immunothérapie en France soit dans un essai clinique soit directement. Après 8 semaines de traitement de l’immunothérapie ciblée à Hallwang, combiné avec une chimiothérapie en France, Alice s’est trouvée en rémission presque complète.

We came to the Hallwang oncology clinic because Alice was treated in France for a very agressive relapse of a triple negative breast cancer in April 2016. Unfortunately the chemotherapy treatment given in France gave no result and it was impossible to have an immunotherapy in France either in a clinical trial or directly. After 8 weeks of targeted immunotherapy treatment in Hallwang combined with a chemotherapy in France, Alice has been in a almost complete remission

Alice and Claude M., France